0001562180-15-000731.txt : 20150908 0001562180-15-000731.hdr.sgml : 20150907 20150908162319 ACCESSION NUMBER: 0001562180-15-000731 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150908 FILED AS OF DATE: 20150908 DATE AS OF CHANGE: 20150908 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tokai Pharmaceuticals Inc CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 255 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-225-4348 MAIL ADDRESS: STREET 1: 255 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kalowski Lee CENTRAL INDEX KEY: 0001618273 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 151097066 MAIL ADDRESS: STREET 1: C/O TOKAI PHARMACEUTICALS, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2015-09-08 false 0001404281 Tokai Pharmaceuticals Inc TKAI 0001618273 Kalowski Lee C/O TOKAI PHARMACEUTICALS, INC. 255 STATE STREET 6TH FLOOR BOSTON MA 02109 false true false false Chief Financial Officer Common Stock 2015-09-08 4 S false 4668.00 13.13 D 40953.00 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.11 to $13.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting. /s/ Cindy Driscoll, Attorney-in-Fact 2015-09-08